Denofosol

In a phase III trial of 352 children with cystic fibrosis, 24 weeks of denufosol raised mean FEV1 by 0.048 L, about 2 percent above baseline, versus 0.003 L in controls. Researchers called the improvement small. Sinusitis, runny nose and headache were more common with the drug.